Alkermes Plc (ALKS)

18.02
NASDAQ : Health Technology
Prev Close 17.29
Day Low/High 17.32 / 18.36
52 Wk Low/High 17.11 / 43.22
Avg Volume 1.28M
Exchange NASDAQ
Shares Outstanding 157.13M
Market Cap 2.72B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes Announces The Appointment Of Richard Gaynor, M.D. And Andy Wilson To Its Board Of Directors And The Retirement Of Director Floyd Bloom, M.D.

Alkermes Announces The Appointment Of Richard Gaynor, M.D. And Andy Wilson To Its Board Of Directors And The Retirement Of Director Floyd Bloom, M.D.

DUBLIN, Sept. 13, 2019 /PRNewswire/ --   Alkermes plc (Nasdaq: ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

-- Patent Trial and Appeal Board Oral Hearing Cancelled --

Alkermes Plc Reports Second Quarter 2019 Financial Results

Alkermes Plc Reports Second Quarter 2019 Financial Results

-- Second Quarter Revenues of $279.9 Million, Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes To Host Conference Call To Discuss Second Quarter 2019 Financial Results

Alkermes To Host Conference Call To Discuss Second Quarter 2019 Financial Results

DUBLIN, July 18, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.

Alkermes Expands Planned New Drug Application For ALKS 3831 To Include Treatment Of Bipolar I Disorder

Alkermes Expands Planned New Drug Application For ALKS 3831 To Include Treatment Of Bipolar I Disorder

-- Following Pre-NDA Meeting With FDA, Company Plans to Submit New Drug Application for Schizophrenia and Bipolar I Disorder Indications in the Fourth Quarter of 2019 --

Alkermes Demonstrates Commitment To Local Community For 11th Consecutive Year With Largest Volunteer Event In Company History

Alkermes Demonstrates Commitment To Local Community For 11th Consecutive Year With Largest Volunteer Event In Company History

WALTHAM, Mass., July 1, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that for the 11 th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater...

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage --

Alkermes To Present New Data From Mental Health Portfolio At The American Society Of Clinical Psychopharmacology 2019 Annual Meeting

Alkermes To Present New Data From Mental Health Portfolio At The American Society Of Clinical Psychopharmacology 2019 Annual Meeting

-- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia --

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FWONA, FWONK, HMN Downgrades: AAME, ABEV, ABR, ALKS, CCS, EXP, PKE, PTR, SCSC, SILC, SMLP, SNMP, TR, TSE Initiations: LAZY, VXRT Read on to get TheStreet Quant Ratings' detailed report:

Alkermes To Present At The UBS Global Healthcare Conference

Alkermes To Present At The UBS Global Healthcare Conference

DUBLIN, May 14, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson, will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at...

Alkermes To Showcase Leadership In Schizophrenia With New Data Presentations At Upcoming Scientific Conferences

Alkermes To Showcase Leadership In Schizophrenia With New Data Presentations At Upcoming Scientific Conferences

-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings --

Alkermes Plc Reports First Quarter 2019 Financial Results

Alkermes Plc Reports First Quarter 2019 Financial Results

-- First Quarter Revenues of $223.1 Million, Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes Appoints Industry Veteran C. Todd Nichols As Senior Vice President Of Sales And Marketing

Alkermes Appoints Industry Veteran C. Todd Nichols As Senior Vice President Of Sales And Marketing

DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that C.

Alkermes To Host Conference Call To Discuss First Quarter 2019 Financial Results

Alkermes To Host Conference Call To Discuss First Quarter 2019 Financial Results

DUBLIN, April 18, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ALKS, AUY, BY, CCS, CXO, DVN, HGV, IESC, KRG, OMF, VRNT Downgrades: ARR, CTG, JAZZ, PTN, ROX Initiations: LBRT, NINE Read on to get TheStreet Quant Ratings' detailed report:

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Law Offices of Howard G. Smith reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the...

Alkermes Larger Than S&P 500 Component Goodyear Tire & Rubber

Alkermes Larger Than S&P 500 Component Goodyear Tire & Rubber

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alkermes plc was identified as having a larger market cap than the smaller end of the S&P 500, for example Goodyear Tire & Rubber Co. , according to The Online Investor.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Alkermes Plc - ALKS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Alkermes Plc - ALKS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc.

American Airlines Is Caught in a Downward Current, Plus 4 Other Stocks That Look Good Short

AAL, UBS, CYOU, LOGM and ALKS were all recently downgraded by TheStreet's Quant Ratings service.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENVA, ERIC, GM, MHH, PJC, SONA, SVVC Downgrades: ALKS, APOG, IDT, MJCO, TYPE Initiations: CKPT Read on to get TheStreet Quant Ratings' detailed report:

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

TheStreet Quant Rating: D (Sell)